Podcasts about FACS

Join Dr. Kristi Funk, M.D., FACS, as she discusses the benefits of exercise in reducing cancer risk and improving overall health. Learn about a study showing how exercise reduces cancer recurrence and mortality rates. Discover how exercise and healthy eating improve chemotherapy outcomes and explore key lifestyle changes to reduce breast cancer risk. Find out about the resources and support available at the Pink Lotus Breast Center, including the Power Up social community, Breast Buddies program, monthly cooking show, and upcoming summit events. #CancerPrevention #ExerciseForHealth #BreastCancerAwareness 

In this episode, Lillian Erdahl, MD, FACS, is joined by Stephanie M Jensen, MD, MPH, and A Britt Christmas, MD, MBA, FACS, from the Carolinas Medical Center, Charlotte, NC. They discuss the recent article by Drs Jensen and Christmas, “Association of State Helmet Laws with Helmet Use and Injury Outcomes in Motorcycle Crashes,” in which the authors analyzed a decade of motorcycle collision data from an American College of Surgeons-verified Level I Trauma Center positioned at the border of 2 states with differing motorcycle helmet laws. The study found that helmeted patients had reduced injury severity, and that state helmet laws significantly influence helmet usage among motorcyclists. Disclosure Information: Drs Erdahl, Jensen, and Christmas, speakers, have nothing to disclose. To earn 0.25 AMA PRA Category 1 Credits™ for this episode of the JACS Operative Word Podcast, click here to register for the course and complete the evaluation. Listeners can earn CME credit for this podcast for up to 2 years after the original air date. Learn more about the Journal of the American College of Surgeons, a monthly peer-reviewed journal publishing original contributions on all aspects of surgery, including scientific articles, collective reviews, experimental investigations, and more. #JACSOperativeWord

Childhood-onset hydrocephalus encompasses a wide range of disorders with varying clinical implications. There are numerous causes of symptomatic hydrocephalus in neonates, infants, and children, and each predicts the typical clinical course across the lifespan. Etiology and age of onset impact the lifelong management of individuals living with childhood-onset hydrocephalus. In this episode, Casey Albin, MD, speaks with Shenandoah Robinson, MD, FAANS, FAAP, FACS, author of the article “Childhood-onset Hydrocephalus” in the Continuum® June 2025 Disorders of CSF Dynamics issue. Dr. Albin is a Continuum® Audio interviewer, associate editor of media engagement, and an assistant professor of neurology and neurosurgery at Emory University School of Medicine in Atlanta, Georgia. Dr. Robinson is a professor of neurosurgery, neurology, and pediatrics at Johns Hopkins University School of Medicine in Baltimore, Maryland. Additional Resources Read the article: Childhood-onset Hydrocephalus Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @caseyalbin Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Albin: Hi, this is Dr Casey Albin. Today I'm interviewing Dr Shenandoah Robinson about her article on childhood onset hydrocephalus, which appears in the June 2025 Continuum issue on disorders of CSF dynamics. Dr Robinson, thank you so much for being here. Welcome to the podcast. I'd love to start by just having you briefly introduce yourself to our audience. Dr Robinson: I'm a pediatric neurosurgeon at Johns Hopkins, and I'm very fortunate to care for kids and children from the neonatal intensive care unit all the way up through young adulthood. And I have a strong interest in developing better treatments for hydrocephalus. Dr Albin: Absolutely. And this was a great article because I really do think that understanding how children with hydrocephalus are treated really does inform how we can care for them throughout the continuum of their lifespan. You know, I was shocked in reading your article about the scope of the problem for childhood onset hydrocephalus. Can you walk our listeners through what are the most common reasons why CSF diversion is needed in the pediatric population? Dr Robinson: For the United States, and Canada too, the most common reasons are spina bifida---so, a baby that's born with a myelomeningocele and then develops associated hydrocephalus---and then about equally as common is posthemorrhagic hydrocephalus of prematurity, congenital causes such as from aquaductal stenosis, and other genetic causes are less common. And then we also have kids that develop hydrocephalus after trauma or meningitis or tumors or other sort of acquired problems during childhood. Dr Albin: So, it's a really diverse and sort of heterogeneous causes that across sort of the, you know, the neonatal period all the way to, you know, young adulthood. And I'm sure that those etiologies really shift based on sort of the subgroup population that you're talking about. Dr Robinson: Yes, they definitely shift over time. Fortunately for our kids that are born with problems that raise concerns, such as myelomeningocele or if they're born preterm, they sort of declare themselves by the time they're a year old. So, if you're an adult provider, they should have defined themselves and it's unlikely that they will suddenly develop hydrocephalus as a teenager or older adult. Dr Albin: Totally makes sense. I think many of the listeners to this podcast are adult neurologists who are probably very familiar with external ventriculostomies for temporary CSF diversion, and with the more permanent ventricular peritoneal shines or ventricular atrial or plural shines that are needed when there's the need for permanent diversion. But you described in your article two procedures that provide temporary CSF diversion that I think many of our listeners are probably not as familiar with, which is the ventricular access devices and ventriculosubgaleal shunts. Can you briefly describe what those procedures provide? Who are the candidates for them? And then what complications neurologists may need to think about if they're consulted for comanagement in one of these complex patients? Dr Robinson: Well, the good thing is that if as an adult neurologist you encounter someone with, you know, residual tubing from one of these procedures, you are unlikely to need to do anything about it. So, we put in ventricular access device or ventriculosubgaleal shunts, usually in newborns or infants. And sometimes when they no longer need the device, we just leave it in because that saves them an extra surgery. So, if you encounter one later on, it's most likely you won't need to do anything. Often if the baby goes on to show that they need a permanent shunt, we go ahead and put in that permanent shunt. We may or may not go back and take out the reservoir or the subgaleal shunt. The reservoir and subgaleal shunts are often put in the frontal location. Sometimes we'll put the permanent shunt in the occipital location and just leave the residual tubing there. So, you're very unlikely to need to intervene with a reservoir or subgaleal shunt if you encounter an older child or adult with that left in. We use these in the small babies because the external ventricular drains that we're very familiar with have a very high complication rate in this population. In the adult ICU, you often see these, and maybe there's, you know, a few percent risk of infection. It actually heads into 20 to 25% in our preterm infants and other newborns that require one of these devices for drainage. So, we try not to use external ventricular drains like we use in older patients. We use the internalized device: either the ventricular reservoir with a little area for us to tap every day, every other day; or the ventriculosubgaleal shunt, which diverts the spinal fluid to a pocket in the scalp. So, we use these in preterm infants that are too tiny for a permanent shunt. And for some of our babies that are born, for example, with an omphalocele, that we can't use their peritoneal cavity and so we need some temporizing device to manage their CSF. Dr Albin: Totally makes sense. And so just to clarify, I mean, this is a tube that's placed into the ventricles of the brain and then it's tunneled into the subgaleal space and the collection, the CSF, just builds up there, like? Dr Robinson: Yeah. Dr Albin: And over time either, you know, the baby will learn how to account for that extra CSF, and then I guess it's just reabsorbed? Dr Robinson: Yeah. When it's present, though, it looks like maybe, I don't know if you're familiar with like a tissue expander. There is this bubble of fluid under the scalp, but it's prominent, it can be several centimeters in diameter. Dr Albin: Wow, that's just absolutely fascinating. And I don't think I've ever had the opportunity to see this in clinical practice. I've really learned quite a bit about this. I assume that these children are going to go on to get some sort of permanent diversion. And then, you know, over time, those permanent shunts do create a lot of problems. And so, I was hoping you could kind of walk us through, you know, what are some of the things that you're seeing that you're concerned about? And then if you've just inherited a patient who had a shunt placed at, say, a different institution, how do you go about figuring out what kind of shunt it is and if they're still dependent on it? Dr Robinson: There's a few things that, fortunately, technology is helping with. So, it is much easier now for patients to get their images uploaded to image-sharing software, and then we can download their images into our institutional software, which is very helpful. Another option is that we are strongly encouraging our families to use a app such as HydroAssist that's available from the Hydrocephalus Association. So that's an app that goes on your phone, and you can upload the images from an MRI or a CT scan or x-rays from a shunt series. And then that you can take if you're traveling and you have to go to emergency department or you're establishing care with a new provider, you can have your information right there and not be under stress to remember it. It also has areas so you can record the type of valve. And all of our valves have pluses and minuses, they all tend to malfunction a little bit. And they can be particularly helpful with different types of hydrocephalus. I really doubt that we're going to narrow down from the fifteen or so valves we have access to now. And so, recording your valve type, the manufacturer as well as the setting, is very helpful when you're transferring care or if you're traveling and then have to, unfortunately, stop in the emergency department. Dr Albin: Yeah, I thought that was a really great pearl that, like, families now are empowered to sort of take control of understanding sort of the devices that they have, the settings that they're using. And what an incredible thing for providers who are going to care for these patients who, you know, unfortunately do end up in centers that are not their primary center. The other challenge that I find… I practice as a neurointensivist, and sometimes patients come in and they have a history of being shunt dependent and they present with a neurologic change. And I think that we as neurologists can be a little quick to blame the shunt and want the shunt to be tapped. And I was really struck in reading this article about the complexity of shunt taps. And I was hoping, you know, can you kind of walk us through what's involved and maybe why we should have a little bit of a higher threshold before just saying, ah, just have the neurosurgeons tap the shunt. Like, it's not that straightforward. Dr Robinson: And it may depend on the population you're caring for. So, when I was at a different institution, we actually published that there's about a 5% complication rate from shunt taps. And that may be- that was in pediatric patients. And again, that may be population dependent, but you can introduce infection to a perfectly clean shunt by doing a shunt tap. You can also cause an acute shunt malfunction. So that's why we tend to prefer that only neurosurgeons are doing shunt taps for evaluation of a shunt malfunction. There are times that, for example, our patients who are getting intrathecal chemotherapy or something have a CSF access device like an Ommaya reservoir, and other providers may tap that reservoir to instill medicine. But that's different than an evaluation, like, you're talking about somebody with a neurological change. And so, it is possible that if somebody has small ventricles or something, if you tap that shunt, you can take a marginally functioning shunt and turn it into an acute proximal malfunction, which is an emergency. Dr Albin: Absolutely. I think that's a fantastic pearl for us to take away from this. It's just that heightened level. And kind of on the flip side of that, you know, and I really- I do feel for us when we're trying to kind of, you know, make a case that it's, it's not the shunt. Many of our shunted patients also have a lot of neurologic complexity, which I think you really talked upon in this article. I mean, these are patients who have developmental cognitive delays and that they have epilepsy and that they're at risk for, you know, complications from prematurity, since that's a very common reason that patients are getting shunts. But from your experience as a neurosurgeon, what are some of the features that make you particularly concerned about shnut malfunction? And how do you sort of evaluate these patients when they come in with that altered mental status? Dr Robinson: It is challenging, especially for our patients that have, you know, some intellectual delay or other difficulties that make it hard for them to give an accurate history. Problem is, if they're sick and lethargic, they may not remember the symptoms that they had when they were sick. But sometimes there's hopefully there's a family member present that does remember and can say, oh, no, this is what they look like when they have a viral illness. And this is different from when they have the shot malfunction, which was projectile emesis, not associated with a fever. It's rare to have a fever with a shunt malfunction, although shunt infection often presents with malfunction. So, it's not completely exclusionary. We often look at the imaging, but it's taking the whole picture together. Some of the common other diagnoses we see are severe constipation that can decrease the drainage from the shunt and even cause papilledema in some people. So, we look at that as well on the shunt series. It's very important to have the shunt series if you're concerned about shunt malfunction or- the shunt tubing is good. It tends to last maybe 20to 25 years before it starts to degrade. And so, you may have had a functioning shunt for decades and it worked well and you're very dependent on it, and then it breaks and you become ill. But on the flip side, we have patients that have had a broken shunt for years, they just didn't know about it. And we don't want to jump in and operate on them and then cause complexities. And so, it is a challenge to sort out. The simplest thing is obviously if they come in and their ventricles are significantly larger, and that goes along with a several-hour or a couple-day deterioration, that's a little more clear-cut. Dr Albin: Absolutely. And you talked about this shunt series. What other imaging- and, sort of maybe walk us through, what's involved in a shunt series, what are you looking at? And then what other imaging is sort of your preferred method for evaluating these patients? Dr Robinson: In adult patients, the shunt series is the x-ray from the entire shunt. And so, if they have an atrial shunt, that would be skull x-ray plus a chest x-ray; or the shunt ends in the perineal cavity, it goes to the perineum. And we're looking for continuity. We're looking for the- sometimes as people grow and age, the ventricular catheter can pull out of the ventricle. So, we're looking to make sure that the ventricular catheter is in an optimal position relative to the skull. We can also look at the valve setting to see the type of valve. So, that can also be helpful as well. And then in terms of additional imaging, a CT scan or an MRI is helpful. If you don't know what type of valve they have, they should not, ideally, go in the MRI scanner. We like to know what their setting is before they go in the MRI because we're going to have to reset the valve after they come out of the MRI if it's a programmable valve. Dr Albin: This is fantastic. I've heard several pearls. So, one is that with the shunt series, which, am I correct in understanding those are just plain X-rays? Dr Robinson: Yes. Dr Albin: Right. Then we can look for constipation, and that might be actually something really serious in a pediatric patient that could clue us in that they could actually be developing hydrocephalus or increased ICP just because of the abdominal pressure. And then that we need to be mindful of what are the stunt settings before we expose anyone to the MRI machine. Is that two good takeaways from all of this? Dr Robinson: Yes. And it's very rare that there'll be an MRI tech that will allow a patient with a valve in the MRI without knowing what it is. So, they have their job security that way. But yeah, if you're not sure, just go ahead and get the CT. Obviously, in our younger kids, we're trying to avoid CT scans. But if you're weighing off trying to decide if somebody has a shunt malfunction versus, you know, waiting 12 or 24 hours for an MRI, go ahead and get the CT. Dr Albin: Absolutely. I love it. Those are things I'm going to take with me for this. I have one more question about these shunts. So, every now and then, and I think you started to touch on this, we will get a shunt series and we'll see that the catheter is fractured. Do the patients develop little- like, a tract that continues to allow diversion even though the catheter is fractured? Dr Robinson: Yes. So, they can develop scar tissue around, and some people have more scar tissue than others. You'll even see that sometimes, say, the catheter has fractured and we'll take out that old fractured tubing and put in new tubing on the other side. But if you go and palpate their neck or chest, you'll still feel that tract is there because it calcifies along the tract. Some patients drain through that calcified tract for weeks or months without symptoms, and then it can occlude off. So, we don't consider it a reliable pathway. It's also not a reliable pathway if you're positioned prone in the OR. So some of our orthopedic colleagues, for example, if they go to do a spine fusion, we like to confirm that the shunt is working before you undergo that long anesthesia, but also that you're going to be positioned prone and you could potentially- you know, the pressure could occlude that track that normally is open. Dr Albin: This is fantastic. I feel like I've gotten everything I've ever wanted to know about shunts and all of their complications in this, which is, you know, this is really difficult. And I think that because we are not trained to put these in, sometimes we see them and we just say, oh, it's fractured that must be a malfunction. But it's good to know that sometimes those patients can drain through, you know, a sort of scarred-down tract, but that it may not be nearly as reliable as when they have the tubing in place. Another really good thing that I'm going to put in my back pocket for the next time I see a patient with a potential shunt malfunction. Dr Robinson: And we do have some patients that the tubing is fractured years ago and they don't need it repaired, and that totally can be challenging when they then transfer to your practice for follow-up care. We tend to follow those patients very closely, both our clinic visits as well as having them seen by ophthalmology. So, there are teenagers and young adults out there that have… their own system has recovered and they are no longer shunt-dependent; and they may have a broken shunt and not actually be using that track, but they usually have had fairly intensive follow up to prove that they're not shunt-dependent. And we still have a healthy respect there that, you know, if they start to get a headache, we're going to take that quite seriously as opposed to, you know, some of our shunt patients, about 10 to 20%, have chronic headaches that are not shunt-related. So, not everybody who has a headache and has a shunt has a shunt malfunction. It's tough. Dr Albin: This is really tough. That actually brings me to sort of the last clinical scenario that I was hoping we could get your perspective on. And I think this would be of great interest to neurologists, especially in the context that these children may develop headaches that have nothing to do with the shunt. I'd like to sort of give you this hypothetical case that I'm a neurologist seeing a patient in clinic and it's a teenager, maybe a young adult, and they had a shunt placed early in childhood. They've done really well. And they've come to me for management of a new headache. And, you know, as part of this workup, their primary care provider had ordered an MRI. And, you know, I look at the MRI, and I don't think that the ventricles look really enlarged. They don't look overdrained. Is having an MRI that looks pretty okay, is that enough to exonerate the shunt in this situation? Dr Robinson: In most cases it is. The one time that we don't see a substantial change in the ventricles is if we have a pseudocyst in the abdomen. The ventricles cannot enlarge initially, and then later on they might enlarge. So, we see that sometimes that somebody will come in and their ventricles will be stable in size, but we're still a little bit suspicious. They've got this persistent headache. They may have, you know, some emesis or loss of appetite, loss of activity, and a slower presentation than you would get with an acute proximal malfunction. We can check an abdominal ultrasound for them. And sometimes, even though the ventricles haven't changed in size, they still have a malfunction because they have that distal pseudocyst. One of the questions that we ask our patients when we're establishing care, in addition to what valve type they have and what sort of their shunt history or other interventions such as endoscopic third ventriculostomy, is to ask if their ventricles enlarge when they have a shunt malfunction. There is a small fraction where they do not. They kind of have a stiff brain, if you will. And so, it's good to know that. That's one of the key factors is asking somebody, do the ventricles enlarge when they have a malfunction? If they have enlarged in the past, they're likely to enlarge again if they have a malfunction. But again, it's not 100%. So, in peds, 20% of the time the ventricles don't enlarge. So, in adults, I'm not that- you know, I don't know what percentage it is, but it's something to consider that you can have a stable ventricular size and still have a shunt malfunction. So, if your clinical judgment, you're just kind of, like, still uneasy, you know, respect that and maybe do a little more workup. That's why we so much want patients to establish care with somebody, whether it's a neurologist or a neurosurgeon or other provider in some areas that have fewer neurospecialists, but to establish care so that you all know what a change is for that patient. That's really important. Dr Albin: That's fantastic. So, to summarize that, it's really important to understand the patient's baseline and how they presented with prior shunt complications, if they've had some. That if they're coming in with a new headache that we don't have a baseline, so, we should just have a heightened level of awareness that, like, the shunt has a start and it has an end. And even if the start of the shunt in the brain looks okay, there still could be the potential for complications in the abdomen. And maybe the third thing I heard from that is that we should look for GI symptoms and sort of be aware of when there could be a complication in the abdomen as well. Does that all sound about right? Dr Robinson: And especially for our kids with spina bifida and for posthemorrhagic hydrocephalus are now adults, because the preterm infants are prone to necrotizing enterocolitis. And they may not have had surgery for it, but they still may have adhesions and other things that predispose them to develop pseudocysts over time. And then our individuals with spina bifida often have various abdominal surgeries and other procedures to help them manage their bowel and bladder function. And so that can also create adhesions that then predisposes to pseudocysts. So, we do have a healthy respect for that. In addition, it used to be---because we have gotten a little better with shunts over time---it used to be, like, when I was in training that you heard, you know, if you haven't had a shunt malfunction for 10 or 15 years, you must- you may no longer be dependent. And that's not really true. There are some people who outgrow their need for shunt dependence, but not everyone does outgrow it. And so, you can be 15, 20 years without a shunt revision and still be shunt-dependent. Dr Albin: Those are fantastic pearls. I think most of them, walking away with this, like, a very healthy respect for the fact that these are complex patients, which the shunt is one component of sort of the things that can go wrong and that we have to have a really healthy respect and really detailed investigation and sort of take the big picture. I really like that. Dr Robinson: Yeah, I know. I think it's- there's a very strong push amongst pediatric neurosurgery and a lot of the related, our colleagues in other areas, to develop multidisciplinary transition clinics and lifespan programs for these patients to help keep everything else optimized so that they're not coming in, for example, with seizures. But then you have to figure out if this is a seizure or a shunt; you know, if we can keep them on track, if we can keep them healthy in all their other dimensions, it makes it safer for them in terms of their shunt malfunction. Dr Albin: Absolutely. I love that, and just the multidisciplinary preventative aspect of trying to keep these patients well. So important. Dr Robinson, I really would like to thank you for your time. We're getting towards the end of our time together. Are there any other points about the article that you just are anxious that leave the readers with, or should I just direct them back to the fantastic review that you've put together on this topic? Dr Robinson: No, I think that we covered a lot of the high points. I think one of the really exciting things for hydrocephalus is that there's a lot of investigations into other options besides shunts for certain populations. We are seeing less hydrocephalus now with the fetal repair of the myelomeningocele, which is great. And we're trying to make inroads into posthemorrhagic hydrocephalus as well. So, there are a lot of great things on the horizon and, you know, hopefully someday we won't have the need to have these discussions so much for shunts. Dr Albin: I love it. I think that's really important. And all of those points were touched on the article. And so, I really invite our listeners to go and check out the article, where you can see sort of, like, how this is evolving in real time. Thank you, Dr Robinson. Please go and check out the childhood-onset hydrocephalus article, which appears in the most recent issue of Continuum on the disorders of CSF dynamics. And be sure to check out Continuum Audio episodes from this and other issues. Thank you again to our listeners for joining us today. And thank you, Dr Robinson. Dr Robinson: Thanks for having me. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from Octane's Ophthalmology Technology Forum with guests Tibor Juhasz, PhD, Richard L. Lindstrom, MD, Sumit “Sam” Garg, MD and Jean-Pierre Hubschman, MD. Welcome to the Eyeluminaries podcast 00:05 Review of episode 33 00:49 Intro of Tibor Juhasz, PhD 01:35 Tell us about your background and how you changed LASIK, cataract and glaucoma surgery. 02:27 How is ViaLase impacting glaucoma treatment? 06:55 How the treatment works 08:24 The importance of having a good team 11:02 Intro of Richard L. Lindstrom, MD 12:58 What is your perspective on what is happening today and what changes are you hoping for? 14:28 Integrated eye care delivery 17:00 Dentistry, a future model for eye care 17:50 Post-graduate medical education is changing 19:09 Was there a technology that you thought was a slam dunk and failed? 23:01 Any technology that you didn't expect to take off? 24:37 Intro of Sumit “Sam” Garg, MD 26:58 What do you see changing in ophthalmology residency programs around the country? 28:52 How do you instruct young physicians to be collaborative in care? 30:42 If you weren't a cornea specialist (or a model) what would you be? 32:10 Advice for young ophthalmologists today? 33:42 Share a Jim Mazzo story with us! 35:28 Intro of Jean-Pierre Hubschman, MD 37:07 Why did you, with a robotics company, decide to start in cataract surgery? 38:23 How do you become more efficient in robotic surgery? 41:00 How do we work on the economic side of this? 43:38 What's it like running a company vs being a retina surgeon? 44:46 Give us your feedback 48:16 Thanks for listening 48:30   Tibor Juhasz, PhD, is the founder and CEO of ViaLase Inc. He was also the co-founder of IntraLase and LenS. Richard L. Lindstrom, MD, is the founder and an attending surgeon at Minnesota Eye Consultants, an adjunct professor emeritus at the University of Minnesota, department of ophthalmology as well as the global chief medical editor of Ocular Surgery News. Sumit “Sam” Garg, MD, is the medical director at the Gavin Herbert Eye Institute at UC Irvine. Jean-Pierre Hubschman, MD, is the co-founder and CEO of Horizon Surgical Systems.   We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm disclosures for Garg, Hubschman, Juhasz, and Lindstrom at the time of publication.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/SYS865. CME/COPE/IPCE credit will be available until June 29, 2026.Eye on Equity: A Comprehensive Approach to DR/DME Care in Under-Represented Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/SYS865. CME/COPE/IPCE credit will be available until June 29, 2026.Eye on Equity: A Comprehensive Approach to DR/DME Care in Under-Represented Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/SYS865. CME/COPE/IPCE credit will be available until June 29, 2026.Eye on Equity: A Comprehensive Approach to DR/DME Care in Under-Represented Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/SYS865. CME/COPE/IPCE credit will be available until June 29, 2026.Eye on Equity: A Comprehensive Approach to DR/DME Care in Under-Represented Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/SYS865. CME/COPE/IPCE credit will be available until June 29, 2026.Eye on Equity: A Comprehensive Approach to DR/DME Care in Under-Represented Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/SYS865. CME/COPE/IPCE credit will be available until June 29, 2026.Eye on Equity: A Comprehensive Approach to DR/DME Care in Under-Represented Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/SYS865. CME/COPE/IPCE credit will be available until June 29, 2026.Eye on Equity: A Comprehensive Approach to DR/DME Care in Under-Represented Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/SYS865. CME/COPE/IPCE credit will be available until June 29, 2026.Eye on Equity: A Comprehensive Approach to DR/DME Care in Under-Represented Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

Driven by her experience on the front lines of surgery, Anahita Dua, MD, MS, MBA, FACS, founded Healthcare for Action, an organization to train and empower healthcare workers to run for public office. As underfunded systems strain patient care, Dr. Dua argues that those who understand medicine can craft the most effective health policy—and she's on a mission to send more clinician-candidates into government over the following years. 

Join Dr. Kristi Funk, M.D., FACS, as she explains how obesity increases cancer risk by focusing on inflammation, estrogen production, and leptin levels. Discover the benefits of exercise in reducing cancer risk, improving overall health, and enhancing chemotherapy outcomes. Learn about key lifestyle changes to lower breast cancer risk and explore the resources and support available at the Pink Lotus Breast Center. #CancerPrevention #HealthyLiving #BreastCancerAwareness

In today's episode, we had the opportunity to speak with Henry M. Kuerer, MD, PhD, FACS, CMQ, about the potential to safely omit surgery in a subset of patients with early-stage HER2-positive or triple-negative breast cancer who achieve a pathologic complete response (pCR) following neoadjuvant systemic therapy. Dr Kuerer is a professor of breast surgical oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. In our conversation, Dr Kuerer reviewed the rationale behind a prospective phase 2 clinical trial (NCT02945579) testing image-guided vacuum-assisted core biopsy to identify patients with no residual disease after neoadjuvant therapy. He outlined the strict technical and eligibility criteria that enabled accurate detection of pCR—including tumors downsizing to less than 2 cm and biopsy of at least 12 cores from the tumor bed—and discussed why this biopsy-based approach may be more reliable than standard surgery in detecting residual disease. He also highlighted the broader clinical implications of the findings, noting that patients with biopsy-confirmed pCR may proceed directly to radiotherapy and avoid breast surgery altogether.

Please visit answersincme.com/VJW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cutaneous oncology discuss the role of emerging immunotherapeutic strategies in treating resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review the current guideline-recommended use of immunotherapies for the management of resectable CSCC; Identify clinical factors that will guide the use of immunotherapeutic approaches for patients with resectable CSCC; Outline proactive strategies to enhance the benefit-to-risk profile of immunotherapy for patients with resectable CSCC; and Describe the evolving role of novel applications of immunotherapy in the treatment of resectable CSCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/VJW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cutaneous oncology discuss the role of emerging immunotherapeutic strategies in treating resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review the current guideline-recommended use of immunotherapies for the management of resectable CSCC; Identify clinical factors that will guide the use of immunotherapeutic approaches for patients with resectable CSCC; Outline proactive strategies to enhance the benefit-to-risk profile of immunotherapy for patients with resectable CSCC; and Describe the evolving role of novel applications of immunotherapy in the treatment of resectable CSCC. This activity is intended for US healthcare professionals only.

In the latest episode of Surgical Readings from SRGS, host Rick Greene, MD, FACS, is joined by Associate Editors Carmelle Romain, MD, FACS, and Manish Raiji, MD, FACS, from the University of Chicago's Department of Surgery. Together, they explore key topics in pediatric surgical care, including necrotizing enterocolitis, intestinal obstruction, pediatric trauma resuscitation, and more. Learn more about Selected Readings in General Surgery, an American College of Surgeons publication that highlights highly relevant and practice-changing information from the world's most prominent medical journals. #SurgicalReadings #SRGS

Neda Shamie, MD, sits down with George O. Waring IV, MD, FACS, for a conversation about his journey from academic medicine to founding the Waring Vision Institute in Charleston, South Carolina. They explore his philosophy toward refractive care, the origin and impact of the term dysfunctional lens syndrome, and how his practice uniquely blends research, surgical innovation, and patient-centered care.

Johnny Franchise on Building Rock-Solid Franchisor-Franchisee RelationshipsEpisode Summary:In this milestone episode of The Advisory Board Podcast, host Dave Hansen finally ropes in a long-time wishlist guest: the one and only Johnny Francis—aka Johnny Franchise. A Swiss Army knife of franchising, Johnny brings decades of wisdom, wit, and hard-earned perspective to a conversation that dives deep into the heartbeat of successful franchise brands: strong, interdependent relationships.Brought to you by our sponsor ClientTether, whose CRM and automation tools help franchisors and franchisees stay connected and thrive together—just like Johnny would recommend.Dave and Johnny explore what makes a franchise brand actually work beyond just a proven model. Spoiler: it's not just about systems—it's about people, trust, and training. Johnny shares why franchisors must obsess over franchisee success, not just ROI, and why continuous training—not just a one-time onboarding—is the unsung hero of brand performance.They also unpack how to spot breakdowns in the relationship ("blame is the first red flag") and why franchise advisory councils aren't just a checkbox—they're a franchisor's secret weapon. Johnny shares stories of turning struggling FACs into collaborative powerhouses and offers simple signals for when your brand needs one (hint: when you can't remember everyone's names).Other gems include:How franchisors can foster innovation from franchisees without triggering chaosThe dangers of an "us vs. them" cultureWhy private equity can both help and hurt—and what to watch forThe underestimated value of showing vulnerability as a leaderJohnny leaves us with one powerful reminder: franchising only works when everyone wins.Want to connect with Johnny?You'll find him at johnnyfranchise.com or on LinkedIn. He's happy to chat—just don't be surprised if you get help before you get an invoice.Huge thanks again to ClientTether for sponsoring this episode. If you're looking to improve franchisee engagement and performance with less manual follow-up and more automation, check them out.

#ThisMorning on #BRN #Wellness #2109 | #Ultra-#Processed #Foods Can #Drive Your #Colorectal #Cancer #Risk | Tim Yeatman, MD, FACS & Ganesh Halade, PhD., USF Health Heart Institute | #Tunein: broadcastretirementnetwork.com #Aging, #Finance, #Lifestyle, #Privacy, #Retirement, #Wellness and #More - #Everyday

In today's episode, supported by Bayer, we had the pleasure of speaking with Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS, about the FDA approval of darolutamide (Nubeqa) plus androgen deprivation therapy for patients with metastatic castration-sensitive prostate cancer (mCSPC). Morgans is the medical director of the survivorship program at Dana-Farber Cancer Institute; as well as an associate professor of medicine at Harvard Medical School, both in Boston, Massachusetts. Shore is the medical director of the Carolina Urologic Research Center. In our exclusive interview, Drs Morgans and Shore discussed the significance of this approval; key efficacy, safety, and quality of life data from the pivotal phase 3 ARANOTE trial (NCT04736199); and how this regulatory decision both opens doors for the treatment of more patients and raises questions about the optimal role of darolutamide in the management of mCSPC. 

In this powerful episode, I sit down with Dr. Stanley Liu, a dentist and a physician, trained as an oral & maxillofacial surgeon and ENT sleep surgeon to discuss a critical (yet often overlooked) part of airway surgery: the muscles that surround—and make up—the airway.We dive into why jaw surgery isn't just about skeletal correction or airway volume. It's about functional muscle rehabilitation. Dr. Liu shares why collaboration with myofunctional therapists before and after surgery is vital for long-term stability, smoother orthodontic care, and patient comfort.You'll learn:-Why focusing only on airway space is a mistake-How pre-surgical myo can reduce post-op complications-What happens when we ignore muscle rehab-And how to build stronger provider collaboration for better outcomesIf you work with surgical cases, airway patients, or post-op relapse concerns—this is the conversation you didn't know you needed.

This episode features a fireside chat with Barbara Lee Bass, MD, FACS, who is the vice president for health affairs, dean of the George Washington University School of Medicine & Health Sciences in Washington, DC, and a past president of the ACS. Dr. Bass talks about what drove her into surgery at a time when very few women were in the profession, why she joined the Army, what it was like to perform her last operation, and why it's essential to be authentic as the leader of a large institution. The program host is Dr. Mohsen Shabahang for the ACS Academy of Master Surgeon Educators.   Talk about the podcast on social media using the hashtag #HouseofSurgery.

Join Dr. Kristi Funk as she breaks down breast cancer risk factors into "Boulders" and "Pebbles." Learn why diet, nutrition, alcohol, exercise, and obesity are major factors, and how you can reduce your risk. This insightful talk empowers you to take control of your health. #BreastCancerAwareness #HealthyLiving #CancerPrevention

Join the Behind the Knife Surgical Oncology Team as we discuss the two key studies investigating optimal management strategies of neuroendocrine tumors of the small bowel. Hosts: - Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center - Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist/HPB surgeon at Kaiser LAMC in Los Angeles. - Connor Chick, MD (@connor_chick) is a 2nd Year Surgical Oncology fellow at Ohio State University. - Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a 1st Year Surgical Oncology fellow at MD Anderson. - Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a PGY-6 General Surgery resident at Brooke Army Medical Center Learning Objectives: In this episode we review two important papers that discuss optimal management strategies of neuroendocrine tumors (NET) of the small bowel.  The first paper by Singh and colleagues discusses the NETTER-2 trial investigating the role of radioligand therapy for NET as a first-line treatment.  The second article by Maxwell et all challenges surgical dogma regarding optimal debulking cutoffs for debulking of NET. Links to Papers Referenced in this Episode: 1.     Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. PMID: 38851203. https://pubmed.ncbi.nlm.nih.gov/38851203/ 2.     Maxwell JE, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016 Jan;159(1):320-33. doi: 10.1016/j.surg.2015.05.040. Epub 2015 Oct 9. PMID: 26454679; PMCID: PMC4688152. https://pubmed.ncbi.nlm.nih.gov/26454679/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

I'm joined today by two special guests to discuss an unusual and ethically complex type of organ donation – imminent death donation, or IDD. As you'll hear Thao Galvan explain in the episode, organ donation currently has three standard types: living donation, donation after brain death (a type of deceased donation in which the patient is declared brain dead, and thus legally dead), and donation after circulatory death, or DCD. In DCD, a patient who is not brain dead is removed from life support, but the heart keeps beating. If it takes the patient more than roughly 90 minutes to die, the organs may not be usable. IDD, or imminent death donation, attempts to prevent that, by retrieving non-vital organs (usually a kidney) for donation prior to the removal of life support. Thao Galvan is a transplant surgeon and professor of surgery at Baylor College of Medicine. Kathy Osterrieder is a retired financial analyst, who came to this issue after attempting, unsuccessfully, to donate the organs of her late husband, Robert Osterrieder, after making the difficult decision to remove him from life support. It is another first for the Taboo Trades podcast – the first time in over five years of recording that I've been unable to hold back the tears, as Kathy talks about what the experience was like for her family. LinksHost: Kimberly D. Krawiec, Charles O. Gregory Professor of Law, University of VirginiaGuests: Nhu Thao Nguyen Galvan, M.D., M.P.H., FACS, Associate Professor of Surgery, Baylor College of MedicineKathleen Osterrieder, Donor Family Member in Spirit, Retired Financial AnalystReading: The Difficult Ethics of Organ Donations From Living Donors, Wall St. J. (2016)Let's change the rules for organ donations — and save lives, Wash. Post (2019)OPTN, Ethical considerations of imminent death donation white paper (2016)Survey of public attitudes towards imminent death donation in the United States, Am. J. Transplant. (2020)

In this episode, Tom Varghese, MD, FACS, is joined by Brett Johnson, MD, and Clifford Ko, MD, FACS, from the American College of Surgeons (ACS). They discuss the recent article by Drs Johnson and Ko, “Evaluating Outcomes of Initial Site Visits Across American College of Surgeons Accreditation Programs,” in which the authors found that ACS accreditation identifies significant gaps in hospital quality, with only 61% of hospitals passing on their initial attempt. However, most ultimately succeed after remediation. These findings highlight that ACS accreditation both validates hospitals meeting rigorous standards and drives quality improvement in those that initially fall short. Disclosure Information: Drs Varghese, speaker, has no relevant financial conflicts to disclose. Drs Johnson and Ko, speakers, are employees of the American College of Surgeons. Learn more about the Journal of the American College of Surgeons, a monthly peer-reviewed journal publishing original contributions on all aspects of surgery, including scientific articles, collective reviews, experimental investigations, and more. #JACSOperativeWord

Guest: Paul Turek, MD, FACS, FRSM, Founder of The Turek Clinic Host: Dan Bulger, Progyny    The Fertility 101 Series, because there's no shortage of daunting terms to keep your mind running, is a quick and dirty breakdown on a specific topic with insights from a fertility expert.  When it comes to fertility, men are half of the equation, but too often, they're the half that gets forgotten or overlooked. This Men's Health Month, we're joined by Dr. Paul Turek, a world-renowned urologist and male fertility expert, to talk all things sperm, from how it's made to how it affects fertility and IVF.  Dr. Turek explains how sperm health isn't just about making babies, it's also a sign of a man's overall health, tied to things like life expectancy, cancer risk, and heart health. Dr. Turek also tells us about his podcast, Talk with Turek, where he and Rob Clyde expose men's health and talk about it frankly – tackling the issues that matter. So, if you want to hear more on men's health from Dr. Turek, you're in luck!  And if you've never thought about getting a semen analysis, this episode might change that. Whether you're thinking about starting a family, planning for the future, or just want to stay healthy, your sperm may tell you more than you could believe.  For more information, visit Progyny's Podcast page and Progyny's Education page for more resources. Be sure to follow us on Instagram, @ThisisInfertilityPodcast and use the #ThisisInfertility. Have a question, comment, or want to share your story? Email us at thisisinfertility@progyny.com.     Video Version: https://youtu.be/VNTff8wEGmk 

My conversation with Dr Dua begins at about 35 mins Stand Up is a daily podcast. I book,host,edit, post and promote new episodes with brilliant guests every day. This show is Ad free and fully supported by listeners like you! Please subscribe now for as little as 5$ and gain access to a community of over 750 awesome, curious, kind, funny, brilliant, generous souls Healthcare For Action was founded in 2022 to support healthcare workers running for Congress. Dr. Anahita Dua, Chair of Healthcare for Action, is a Vascular Surgeon at Massachusetts General Hospital and an Associate Professor of Surgery at Harvard University. As a surgeon, she knows that in order to get things done and save lives, the surgery team has to work together and take action. Our politics shouldn't be any different.  In 2023, Healthcare For Action merged with Doctors In Politics, founded in 2020 by a group of physicians specializing in psychiatry, family medicine, OBGYN, and neurology. They were committed to patient-centered and equitable political change at all levels of government and grew to a membership of nearly 10,000. We believe fundamentally that all policy is health policy.  There are too many existential threats facing our democracy. From reversing climate change, preserving access to abortion, and curbing the epidemic of gun violence we must take action now and play the long game. From acute care to prevention, healthcare workers know how to get the job done. That is the guiding vision of the largest Democratic healthcare workers PAC in the country - Join our community at Healthcare For Action! Anahita Dua, MD, MS, MBA, FACS, is a vascular surgeon at Massachusetts General Hospital and an associate professor of Surgery at Harvard Medical School. At Mass General, she is the director of the Vascular Lab, co-director of the Peripheral Artery Disease Center and Limb Evaluation and Amputation Program (LEAPP), associate director of the Wound Care Center, director of the Lymphedema Center and associate director of the Vascular Surgery Clerkship and director of clinical research for the division of vascular surgery. She specializes in advanced endovascular (minimally invasive) and traditional (open) limb salvage techniques for treating peripheral arterial disease and critical limb ischemia, diabetic limb disease, aortic disease, carotid disease, thoracic outlet syndrome and venous disease. Dr. Dua completed her vascular surgery fellowship at Stanford University Hospital, her general surgery residency at the Medical College of Wisconsin and her medical school in the United Kingdom. She has also completed a master's degree in trauma sciences, a master's in business administration in health care management and has a certificate in health economics and outcomes research as well as a certificate in drug and device development from the Massachusetts Institute of Technology. She is board-certified in vascular surgery, general surgery and advanced wound care and management. Dr. Dua has published over 140 peer reviewed papers and has edited five vascular surgery medical textbooks. She serves on multiple national vascular surgery committees through the Society for Vascular Surgery and other vascular organizations including the South Asian-American Vascular Society and American College of Surgeons. Dr. Dua's lab focuses on anticoagulation and biomarkers that are predictive of thrombosis and hemostasis in patients that have undergone revascularization. She is interested in creation precision, point of care medical approaches to anticoagulation for patients post revascularization. Her clinical and outcomes research focuses primarily on diseases involving peripheral vascular disease, limb salvage and critical limb ischemia. She is part of a technology development team that creates tools to increase walking distance and wound healing while decreasing pain in patients with peripheral vascular disease. Dr. Dua is also involved heavily in surgical outcomes-based research using large medical databases to generate both quality outcomes and cost effectiveness data. Dr. Dua is a self-described animal lover and rescuer of pitbulls. At one point, she housed 14 pitbull puppies and their mother at once. Nowadays, her spare time is spent with her husband, son, daughter and dog Leo. Join us Monday and Thursday's at 8EST for our  Bi Weekly Happy Hour Hangout!  Pete on Blue Sky Pete on Threads Pete on Tik Tok Pete on YouTube  Pete on Twitter Pete On Instagram Pete Personal FB page Stand Up with Pete FB page All things Jon Carroll  Follow and Support Pete Coe Buy Ava's Art  Hire DJ Monzyk to build your website or help you with Marketing  

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

Dr. Alipi Bonm, a neuro-oncologist at the Providence Swedish Cancer Institute in Seattle, joins host Dr. Ashwani Rajput to offer up valuable insights into brain cancer, from what to expect to the promising treatment options available that could ease your fears. He also debunks common myths, such as the misconception that cell phones and electrical wires cause brain cancer and highlights promising future treatments. If you or a loved one are affected by brain cancer, discover the support groups available for both patients and caregivers. Don't miss out on this informative and supportive discussion.Dr. Ashwani Rajput BioSee below Do you want to know more?Check out the Providence blog for more information on melanoma and other cancer related topics. Personalized cancer peptide vaccine shows remarkable promise against glioblastomaProvidence Saint John's opens last phase of clinical trial of promising drug for aggressive brain cancerTo learn more about our mission programs and services, go to Providence.org.Follow us on social media to get continued information on other important health care topics. You can  connect with us on LinkedIn, Facebook, TikTok, Instagram and X.For all your healthcare information on the go, download the Providence app. Whether you're tracking symptoms, scheduling appointments, or connecting with your healthcare providers, the Providence app has your back.To learn more about the app, check out the Wellness Brief podcast episode. Wellness Brief: Simplifying Care-There's an App for That.We'd love to hear from you. You can contact us at FutureOfHealthPodcasts@providence.org Dr. Ashwani Rajput BioAshwani Rajput, MD, FACS, joined Providence Swedish in September 2024 as the regional executive medical director (EMD) of the Swedish Cancer Institute. Dr. Rajput comes to us from Johns Hopkins University, where he is a professor of Surgery and Oncology, as well as the director of the Hopkins Kimmel Cancer Center in the Washington, D.C. region. Dr. Rajput completed his medical school, general surgery training, and a post-doctoral fellowship in molecular genetics at Case Western Reserve University in Cleveland, Ohio. He went on to the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., for a fellowship in Complex General Surgical Oncology (CGSO). There, he was recruited to join the faculty at Roswell Park with appointments in GI Surgical Oncology as well as Pharmacology and Therapeutics. His laboratory investigated the key signal transduction pathways in colorectal metastases using novel orthotopic murine models. In 2009, Dr. Rajput was recruited to the University of New Mexico as the inaugural division chief of Surgical Oncology. During his tenure in New Mexico, he also served as the director of surgical services for the NCI-designated Comprehensive Cancer Center and vice-chair of surgery for academic affairs and faculty development. Under his leadership, an ACGME-approved fellowship in CGSO was created and launched. Throughout his roles in New Mexico and D.C., he has actively addressed cancer health care outcomes and health equity. Under Dr. Rajput's leadership, he will develop and implement a cancer strategic vision and enhance collaboration across our geography. He will oversee the SCI medical directors and partner with the Senior Director of Operations to deliver excellence in cancer care. Dr. Rajput and his wife, Sunita, have four children. Outside of work, he enjoys playing tennis, piano, the arts, and traveling.

Join Dr. Kristi Funk as she debunks the myth about protein intake and reveals top plant-based sources. Learn why you don't need to worry about protein deficiency and discover the power of soy, lentils, beans, and more. Transform your diet with these delicious and nutritious options! #PlantBasedProtein #HealthyEating #BreastCancerPrevention

Dr. Tracy Gapin, MD, FACS, is a renowned expert in men's health optimization and longevity, with over 25 years of experience as a board-certified urologist. He founded the Gapin Institute to help high-performing individuals, including entrepreneurs, executives, and athletes, achieve peak performance through personalized health programs. Dr. Gapin integrates advanced diagnostics, epigenetics, hormone therapy, and wearable technology to monitor and transform his clients' health, focusing on sustainable, measurable outcomes. A thought leader and author of bestsellers Male 2.0 and Codes of Longevity, Dr. Gapin has been featured on NBC, Entrepreneur Magazine, and at Dave Asprey's Biohacking Conference. He is a member of the American Academy of Anti-Aging, the Age Management Medical Group, and the International Peptide Society. In this episode Dr. Tracy dives in to talk about what re-shaped his thinking on the traditional reactive medical system, and the path he was inspired to take to become a proactive solution for high-performing entrepreneurs and leaders. Dr. Tracy walks us through how we may overestimate what we think we know about our health which are our health blind spots. These can show up when we dive deeper beyond the surface to explore things such as hormones, inflammation, and our gut health. Dr. Tracy shares his personal story of dis-ease and what it finally took for him not only to face his health head-on but also the medical system he operated within. Patrick and Dr. Tracy explore his paradigm shift around men's and women's health, endocrine disruptors, peptides, protein and carbs, aging and regenerative medicine. They round out their conversation with mindset – habits, choice, discipline and transformation. You don't want to miss it!

James R. Korndorffer Jr., M.D., MHPE, FACS, joined the University of Texas Austin, Dell Medical School in January of 2025 and leads the continuum of medical education to train the next generation of physicians and health care professionals. In addition, he leads efforts across The University of Texas at Austin and The University of Texas System to support interprofessional education, curricular innovation, research and other learning activities.Korndorffer graduated cum laude from Tulane University with an undergraduate degree in biomedical engineering. He received his medical degree from the University of South Florida College of Medicine. He completed his general surgery internship and residency at the Carolinas Medical Center in Charlotte, North Carolina, where he received the award for best resident teacher.With a strong interest in teaching, Korndorffer left a successful private practice after eight years and joined the faculty at Tulane University School of Medicine He became an associate professor of surgery in 2005 and professor in 2010. He served in numerous leadership roles at Tulane, including vice chair of the surgery department from 2012 to 2017, program director for the surgical residency from 2006 to 2017, assistant dean for graduate medical education and founding medical director for the Tulane Center for Advance Medical Simulation. Continuing his passion for education, Korndorffer completed his Master of Health Professions Education at the University of Illinois Chicago while working full time at Tulane.Korndorffer joined Stanford School of Medicine's Department of Surgery as the inaugural vice chair for education in 2017. He assumed additional leadership responsibilities within the department, including director of the Goodman Surgical Simulation Center and the surgical education fellowship program.He was one of the early adopters of the use of simulation for surgical training and has been actively involved in surgical education research since 2003. Some of the early work using proficiency-based training instead of time base training for skill acquisition. This has now become the norm. He is now actively involved investigating the role simulation education has in patient quality and healthcare system safety.Korndorffer has published over 100 papers in peer-reviewed journals as well as 10 book chapters, and he has held over 150 presentations at national and international meetings.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

In this episode, Tom Varghese, MD, FACS, is joined by Todd Heniford, MD, FACS, and Alexis Holland, MD, from the Carolinas Medical Center. They discuss the recent article by Drs Heniford and Holland, “Limited or Lasting: Is Preoperative Weight Loss as Part of Prehabilitation Maintained after Open Ventral Hernia Repair?” This study supports the implementation of preoperative optimization and weight loss before hernia surgery, which remains controversial. Long-term maintenance of preoperative weight loss before abdominal wall reconstruction is achievable and sustainable.   Disclosure Information: Drs Varghese and Holland have nothing to disclose. Dr Heniford is a surgical research grant recipient and receives speaking honoraria from WL Gore.   To earn 0.25 AMA PRA Category 1 Credits™ for this episode of the JACS Operative Word Podcast, click here to register for the course and complete the evaluation. Listeners can earn CME credit for this podcast for up to 2 years after the original air date. Learn more about the Journal of the American College of Surgeons, a monthly peer-reviewed journal publishing original contributions on all aspects of surgery, including scientific articles, collective reviews, experimental investigations, and more.   #JACSOperativeWord

In this episode John A. Hovanesian, MD, FACS, and Jim Mazzo are live from SightLine at the ASCRS meeting with guests Nicole R. Fram, MD, Kerry D. Solomon, MD, Vance Thompson, MD, and Steve Speares. Welcome to the Eyeluminaries podcast 00:02 Review of episode 32 00:55 Intro of Nicole Fram, MD 01:16 Tell us why the MAHRVELS team is likely to be the leading fundraisers and why you picked your character for the team to portray (The Scarlet Witch)? 02:24 Meeting about complications from cataract surgery, what do you think is the next big phase on how we're going to handle complications with technology? 04:05 Psychology of managing patients/conveying care 05:42 What advice do you give to people who are starting their career? 06:50 Intro of Kerry Solomon, MD 09:30 What do we often get wrong with cataract surgery and what do we often get right? 10:25 How do you stay an entrepreneur and a leading physician? 11:55 What is Operation Sight? How did you create it? 14:19 Where will keratorefractive surgery and lens-based surgery be in 5 or 10 years? 18:30 Intro of Vance Thompson, MD 21:24 What's it like to be ASCRS president? 21:59 What is BRiCS and why is it important? 23:54 You've created a culture; can you talk about that culture you've created at your institute? 29:30 Tell us about your winery! 33:28 Intro of Steve Speares 36:45 ASCRS just wrapped up. Your idea of creating a SightLine with a business approach, what did you do and what was the idea? 38:00 As you look back and you look ahead, what changes do you hope to make? What do you hope your legacy will be at ACSRS? 40:57 Can you expand more on how Washington, DC and Trump administration will impact your society/group? 44:19 Richard Lindstrom in ASCRS hall of fame, tell us your own perspective and a good story 46:29 Preview of episode 34 52:09 Give us your feedback 52:40 Thanks for listening 52:56 Nicole Fram, MD, is an adjunct assistant professor at the John A. Moran Eye Institute at the University of Utah. She is also the secretary for ASCRS, is a member of the Cataract Clinical Committee, and leads the Ophthalmology Quicksand Chronicles podcast with co-host Elizabeth Yeu, MD. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Kerry Solomon, MD, is internationally renowned for LASIK and refractive cataract surgery. He is the co-founder of Operation Sight. He is the former chairman of the ASCRS FDA Committee. Steve Speares, MD, is the executive director at ASCRS. Vance Thompson, MD, is the founder of Vance Thompson Vision and director of refractive surgery in Sioux Falls, SD. He serves as a professor of ophthalmology at the Sanford School of Medicine at the University of South Dakota. Thompson is the immediate past president of ASCRS. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Fram, Speares, Solomon, and Thompson at the time of publication.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CBJ865. CME/AAPA/IPCE credit will be available until May 27, 2026.Personalizing Prostate Cancer Care: Real-World Approaches for the Community Urology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CBJ865. CME/AAPA/IPCE credit will be available until May 27, 2026.Personalizing Prostate Cancer Care: Real-World Approaches for the Community Urology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CBJ865. CME/AAPA/IPCE credit will be available until May 27, 2026.Personalizing Prostate Cancer Care: Real-World Approaches for the Community Urology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

In this episode of Quah (Q & A), Sal, Adam & Justin coach four Pump Heads via Zoom. Mind Pump Fit Tip: 8 weird signs that you should avoid gluten. (1:45) Why is fitness so EFFECTIVE for depression and anxiety? (22:07) Don't forget to bring Zbiotics to your next party or gathering. (29:00) The Schafer's Lego Land experience. (32:19) Saffron is a natural compound for depression and anxiety. (45:43) Justin's Road to 315 Push Press. (46:55) 3-part bonus series for trainers dropping on May 19th! (1:00:35) #ListenerLive question #1 – Any advice for jumping and getting into personal training? (1:01:51) #ListenerLive question #2 – Where do I go after I finish Symmetry to make sure I can keep this momentum going to live pretty much pain-free and moving freely? (1:13:03) #ListenerLive question #3 – When would you guys recommend someone get liposuction? (1:22:42) #ListenerLive question #4 – Do I need to educate myself a little more before hiring a coach? And if so, how exactly? (1:32:53) Related Links/Products Mentioned Ask a question to Mind Pump, live! Email: live@mindpumpmedia.com Visit Pre-Alcohol by ZBiotics for an exclusive offer for Mind Pump listeners! ** Promo code MINDPUMP25 for 15% off first-time purchasers on either one-time purchases, (3, 6, 12-packs) or subscriptions (6, 12-pack) ** Visit Organifi for the exclusive offer for Mind Pump listeners! **Promo code MINDPUMP at checkout for 20% off** May Special: MAPS 15 Performance or RGB Bundle 50% off! ** Code MAY50 at checkout ** Mood Disorders and Gluten: It's Not All in Your Mind! A Systematic Review with Meta-Analysis Transmission of Faith in Families: The Influence of Religious Ideology Effects of Saffron Extract Supplementation on Mood, Well-Being, and Response to a Psychosocial Stressor in Healthy Adults: A Randomized, Double-Blind, Parallel Group, Clinical Trial Justin's Road to 315 Push Press Train the Trainer Webinar Series Mind Pump Group Coaching Mind Pump #2515: How to Become a Successful Trainer in 2025 Online Personal Training Course | Mind Pump Fitness Coaching ** Approved provider by NASM/AFAA (1.9 CEUs)! Grow your business and succeed in 2025. ** Mind Pump #2242: The Non-Surgical Way to Look Younger With Dr. Anthony Youn Mind Pump #1622: Nine Signs Your Trainer Sucks Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned Stan “Rhino” Efferding (@stanefferding) Instagram Jordan Jiunta (@redwiteandjordan) Instagram Marcelo (@mindpumpmarcelo) Instagram Anthony Youn, MD, FACS (@tonyyounmd) Instagram Justin Brink DC (@dr.justinbrink) Instagram Jordan Shallow D.C (@the_muscle_doc) Instagram  

Cancer is among the most common and feared diseases in the modern world. Dr. Selwyn Vickers—president and CEO of Memorial Sloan Kettering Cancer Center—joins host Mark Labberton to discuss how precision oncology, data, and faith are transforming cancer treatment. A distinguished cancer surgeon and pancreatic cancer researcher, Vickers explains how groundbreaking advances in genomics, immunotherapy, and AI are transforming once-lethal diagnoses into survivable and even chronic conditions. Together, they explore not only the cutting-edge science of cancer care but also the spiritual, emotional, and social dimensions that affect every patient and caregiver. Resonating with themes of suffering, hope, and resurrection, this conversation offers clarity, compassion, and courage for all who are affected by cancer—from those newly diagnosed, to medical professionals, to grieving families and curious listeners. Episode Highlights “We're getting to a point where we will, in the next five to seven years, have a much better chance to cure people—and to make pancreatic cancer a chronic illness.” “We are in what's somewhat coined the golden age of cancer research.” “Cancer is a disease that creates an existential threat in ways no other illness does.” “If a tumour forms, it means your body's immune system has made a social contract with the cancer.” “We changed the diagnosis in 10–12 percent of the patients who come to us—sometimes from cancer to no cancer.” “Cancer care is a team sport. And our patients often inspire us more than we help them.” Helpful Links & Resources Memorial Sloan Kettering Cancer Center BioNTech – creators of mRNA vaccines for COVID and cancer CAR T-Cell Therapy Overview (Cancer.gov) Tim Keller on cancer and hope Emma Thompson's Wit (HBO) BRCA1 and BRCA2 Genes and Cancer Risk MSK-IMPACT: Next-Gen Tumor Profiling About Selwyn Vickers Selwyn M. Vickers, MD, FACS, is the president and CEO of Memorial Sloan Kettering Cancer Center (MSK) and the incumbent of the Douglas A. Warner III Chair. He assumed the role on September 19, 2022. Vickers is an internationally recognized pancreatic cancer surgeon, pancreatic cancer researcher, and pioneer in health disparities research. He is a member of the National Academy of Medicine and the Johns Hopkins Society of Scholars. He has served on the Johns Hopkins School of Medicine Board of Trustees and the Johns Hopkins University Board of Trustees. Additionally, he has served as president of the Society for Surgery of the Alimentary Tract and the Southern Surgical Association. Vickers is the immediate past president of the American Surgical Association. He also continues to see patients. In 1994, he joined the faculty of the University of Alabama at Birmingham (UAB) as an assistant professor in the Department of Surgery, where he was later appointed to professor and the John H. Blue Chair of General Surgery. In 2006, Vickers left UAB to become the Jay Phillips Professor and Chair of the Department of Surgery at the University of Minnesota Medical School. Born in Demopolis, Alabama, Vickers grew up in Tuscaloosa and Huntsville. He earned baccalaureate and medical degrees and completed his surgical training (including a chief residency and surgical oncology fellowship) at the Johns Hopkins University. Vickers completed two postgraduate research fellowships with the National Institutes of Health and international surgical training at John Radcliffe Hospital of Oxford University, England. Vickers and his wife, Janice, who is also from Alabama, have been married since 1988. They have four children. Show Notes The ongoing threat and fear of cancer How Selwyn Vickers got into medicine Pancreatic cancer: Vickers's expertise “We are in what's somewhat coined the golden age of cancer research.” Sequencing the human genome “Is there a drug that might target the mutation that ended up creating your cancer?” Cancer as both a medical and existential diagnosis The revolution of precision oncology through human genome sequencing ”It takes a billion cells to have a one centimetre tumor.” Immunotherapy: checkpoint inhibition, CAR T-cell therapy, and vaccines Cellular therapy:   ”Taking a set of their normal cells and re-engineering them to actually go back and target and attack their tumors. … We've seen patients who had initially a 30 percent chance of survival converted to an 80 percent chance of survival.” “We know in many tumours there's something called minimal residual disease.” “Immunizing yourself against cancer is a significant future opportunity.” Managing the power of data with AI and computational oncology Cancer-care data explosion: the role of computational oncologists Cancer vaccines: breakthrough mRNA treatment for pancreatic cancer ”Didn't ultimately win. We had to suffer through her losing her life, but was so appreciative that she got much more than the six months she was promised.” Tumour misdiagnoses and the importance of specialized expertise Pancreatic cancer challenges: immune cloaking and late-stage detection In the past, one in four would die from the operation for removing pancreatic cancer Long-term survival Future of cancer detection: AI-based medical record analysis and blood biopsies More accurate blood tests to confirm conditions Using AI to select those who are high-risk for cancer Pastor Tim Keller died of pancreatic cancer. In the past, “your doctor … helped you learn how to die.” ”[God's] given man the privilege to discover those things that have been hidden. And over time we've gradually uncovered huge opportunities to impact people's lives.” The state of breast cancer research and treatment “If you get the diagnosis of breast cancer, you have a 90 percent chance to survive and beat it over a five-year period of time.” ”In general, we're in a great state of understanding how to treat breast cancer, how to detect it early, and then have selective and targeted mechanisms to prevent it from coming back.” Prostate cancer research and treatment Theranostics: using a specific antibody to target cancer cells specifically Pediatric cancer:  ”We actually treat more children for cancer than any hospital in America now, but in general, the survival for pediatric cancers is greater than 80 percent.” Emotional, psychological, and spiritual toll of cancer: importance of psycho-oncology How Sloan Kettering developed psycho-oncology to help cancer patients with mental and spiritual health Personal story: how a cafeteria worker empowers patients through food choices “We give back to them the right to choose what they get to have on their tray.” Cancer treatment is a team sport. Wit (film, Broadway play)—actress Emma Thompson plays a cancer patient studying the work of John Donne on death Socioeconomic and racial disparities in cancer care outcomes The healing role of community, support teams, and compassionate listening The importance of listening to cancer patients who are preparing to die The spiritual courage of patients and the transformative power of faith “Our patients often help us. We see the grace with which they often handle that journey.” The inspiration behind becoming a doctor: family legacy and human impact Terminal care: the sacred responsibility of walking with patients to the end Cancer research and treatment as a Christian vocation and expression of humanity Production Credits

Raeann Wilson was born in Cabot, AR. As a breast cancer survivor, IV therapy was an integral part of Raeann's recovery, and she became passionate about giving the same level of care to other post-operation patients. As the surgical coordinator at Shewmake Plastic Surgery, Raeann has extensive knowledge in surgical processes and patient care. This all gave her the skill and inspiration to create Zen Infusion, offering mobile, on-demand IV infusion therapy that serves a number of needs for the people of Central Arkansas. Kris Shewmake, M.D., FACS was born in Pine Bluff, AR. He earned his bachelor's degree in biology from Hendrix College in Conway and a master's degree in natural science from the University of Arkansas at Fayetteville. He received his medical degree from UAMS, where he also completed a residency in general surgery. He was president of his class and elected into the Alpha Omega Alpha Medical Honor Society (top 10% of the class). His eight years of surgical training after medical school included a General Surgery residency at the University of Arkansas for Medical Sciences (UAMS) Medical Center and a Plastic and Reconstructive Surgery residency in Dallas at the University of Texas-Southwestern Medical Center. Dr. Shewmake entered private practice in 1996 and was named Best Plastic Surgeon in Arkansas by his colleagues in 1999 and 2009.

In this episode, Arthur L. Jenkins III, MD, FACS, FAANS, Director of Spine Program at Institutes for Specialized Surgery, LLC, joins the podcast to discuss how he's working to simplify the surgery experience for patients. He also dives into his focus on clinical and operational excellence, the political climate surrounding the healthcare space, and pay discrepancies tied to volume over quality.

Are you struggling with chronic constipation, incomplete evacuation or irregular bowel movements despite trying diet and lifestyle changes? These symptoms might point to underlying issues with gut motility, nervous system signaling or imbalances in the gut microbiome. Gain a clearer understanding of your digestive health and learn about the physiology, causes and solutions for improving bowel function and avoiding hemorrhoids and anal fissures with Dr. Carmen Fong, MD, FACS. Lindsey Parsons, your host, helps clients solve gut issues and reverse autoimmune disease naturally. Take her quiz to see which stool or functional medicine test will help you find out what's wrong. She's a Certified Health Coach at High Desert Health in Tucson, Arizona. She coaches clients locally and nationwide. You can also follow Lindsey on Facebook, Tiktok, X, Instagram or Pinterest or reach her via email at lindsey@highdeserthealthcoaching.com to set up your free 30-minute Gut Healing Breakthrough Session. Show Notes

   What if protecting a soldier's vision was as critical as shielding them from bullets? Join us as we promise a journey with retired Army Colonel and ophthalmologist, Dr. Robert Mazzoli, whose remarkable career in military medicine sheds light on the evolution of ophthalmology on the battlefield. Dr. Mazzoli's story, from his humble beginnings in Louisville, Kentucky to his pivotal role in military ophthalmology, offers an inspiring testament to the importance of education and adaptability in the face of changing warfare dynamics.    Discover the fascinating advancements in eye protection technology, as we trace the journey from the Vietnam War's primitive solutions to today's sophisticated polycarbonate eyewear. This conversation uncovers the cultural shifts and scientific breakthroughs that have revolutionized eye safety for military personnel. Dr. Mazzoli shares his insights into the complexities of treating ocular trauma and the transformative impact of regenerative medicine and telemedicine, which are reshaping how ocular injuries are managed in remote and hostile environments.    As we explore the challenges of vision rehabilitation within both military and VA systems, we address the ongoing efforts to integrate military ocular trauma expertise into civilian care. Dr. Mazzoli's perspective on the necessity of collaboration highlights the potential for military innovations to benefit the larger healthcare community. This episode is a compelling exploration of the past, present, and future of military ophthalmology, emphasizing the critical need for specialized training and collaborative care in ensuring the vision survival of soldiers.   Chapters: (00:03) Military Medicine and Ophthalmology Evolution (16:02) Advancements in Eye Protection Technology (26:03) Enhancing Ophthalmology in Military Deployments (31:11) Complex Care of Ocular Trauma (44:50) Vision Rehabilitation Challenges and Progress (51:12) Transformative Impact of Military Ophthalmology   Chapter Summaries: (00:03) Military Medicine and Ophthalmology Evolution Retired Army Colonel and ophthalmologist Dr. Robert Mazzoli discusses the role of ophthalmologists in combat, ocular injuries, and future advancements in regenerative medicine and telemedicine.   (16:02) Advancements in Eye Protection Technology Evolution of warfare, advancements in eye protection, challenges in adoption, and influence of modern military culture.   (26:03) Enhancing Ophthalmology in Military Deployments Evolution of military ophthalmology from Vietnam War to modern conflicts, challenges in providing care, advancements in deployment kits, and future needs for ocular injury management on a mobile battlefield.   (31:11) Complex Care of Ocular Trauma Ophthalmology subspecialties, ocular trauma in military settings, need for collaboration, damage control, and adaptability in deployed settings.   (44:50) Vision Rehabilitation Challenges and Progress Military and VA face challenges in coordinating vision rehab, relying on VA facilities and exploring advancements in regenerative medicine.   (51:12) Transformative Impact of Military Ophthalmology Telemedicine transforms military eye care, allowing collaboration and integration for ocular trauma treatment globally and in civilian systems.   Take Home Messages: The Critical Role of Vision in Combat: The episode underscores the essential role of vision for combat effectiveness. Vision is vital on the battlefield, with the potential to drastically impact a soldier's ability to perform and survive. The podcast highlights the strategic importance of protecting soldiers' eyesight to maintain operational readiness and effectiveness. Advancements in Eye Protection Technology: The journey of eye protection technology from early ineffective designs to modern polycarbonate solutions is explored. These advancements have significantly enhanced eye safety for military personnel, reducing the occurrence and severity of ocular injuries in combat zones. Challenges and Innovations in Military Ophthalmology: The evolution of military ophthalmology from past conflicts to the present is examined, emphasizing the need for comprehensive care and specialized training. The discussion touches on the importance of adapting to evolving warfare dynamics and the future potential of telemedicine and regenerative medicine in providing efficient ocular trauma care. Complexity of Ocular Trauma Care: The podcast delves into the intricacies of managing ocular trauma in military settings, highlighting the necessity for collaborative efforts among various ophthalmology subspecialists. The challenges of dealing with blast injuries and the importance of damage control ophthalmology are discussed, emphasizing the need for well-rounded ophthalmologists in deployed environments. Vision Rehabilitation and Future Prospects: The episode addresses the logistical and organizational challenges of vision rehabilitation within military and VA systems, especially for those affected by ocular trauma. It also explores the promising, yet early-stage, advancements in regenerative medicine, including stem cell research and whole eye transplants, as potential future solutions for vision restoration.   Episode Keywords: Military Ophthalmology, Dr. Rob Mazzoli, eye care advancements, vision rehabilitation, battlefield medicine, eye protection technology, telemedicine in military, regenerative medicine, ocular trauma care, military healthcare, veteran eye health, combat zone innovations, polytrauma management, military deployments, ocular innovation   Hashtags: #MilitaryMedicine #Ophthalmology #EyeCare #VisionOnTheFrontlines #Telemedicine #RegenerativeMedicine #BattlefieldInnovation #EyeProtection #VeteranHealth #CombatVision Honoring the Legacy and Preserving the History of Military Medicine The WarDocs Mission is to honor the legacy, preserve the oral history, and showcase career opportunities, unique expeditionary experiences, and achievements of Military Medicine. We foster patriotism and pride in Who we are, What we do, and, most importantly, How we serve Our Patients, the DoD, and Our Nation.   Find out more and join Team WarDocs at https://www.wardocspodcast.com/ Check our list of previous guest episodes at https://www.wardocspodcast.com/our-guests Subscribe and Like our Videos on our YouTube Channel: https://www.youtube.com/@wardocspodcast Listen to the “What We Are For” Episode 47. https://bit.ly/3r87Afm   WarDocs- The Military Medicine Podcast is a Non-Profit, Tax-exempt-501(c)(3) Veteran Run Organization run by volunteers. All donations are tax-deductible and go to honoring and preserving the history, experiences, successes, and lessons learned in Military Medicine. A tax receipt will be sent to you. WARDOCS documents the experiences, contributions, and innovations of all military medicine Services, ranks, and Corps who are affectionately called "Docs" as a sign of respect, trust, and confidence on and off the battlefield,demonstrating dedication to the medical care of fellow comrades in arms.     Follow Us on Social Media Twitter: @wardocspodcast Facebook: WarDocs Podcast Instagram: @wardocspodcast LinkedIn: WarDocs-The Military Medicine Podcast YouTube Channel: https://www.youtube.com/@wardocspodcast